762 related articles for article (PubMed ID: 33761582)
1. Super-rapid race for saving lives by developing COVID-19 vaccines.
Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A
J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
3. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
4. Coronavirus Vaccine: Light at the End of the Tunnel.
Ella KM; Mohan VK
Indian Pediatr; 2020 May; 57(5):407-410. PubMed ID: 32291382
[TBL] [Abstract][Full Text] [Related]
5. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
6. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
7. [SARS-CoV-2 vaccines].
Benfield TL; Helweg-Larsen J
Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
[TBL] [Abstract][Full Text] [Related]
8. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
[TBL] [Abstract][Full Text] [Related]
9. Deciphering Vaccines for COVID-19: where do we stand today?
Baviskar T; Raut D; Bhatt LK
Immunopharmacol Immunotoxicol; 2021 Feb; 43(1):8-21. PubMed ID: 33054486
[TBL] [Abstract][Full Text] [Related]
10. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
Russell RL; Pelka P; Mark BL
Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
[TBL] [Abstract][Full Text] [Related]
11. mRNA vaccines for COVID-19: what, why and how.
Park JW; Lagniton PNP; Liu Y; Xu RH
Int J Biol Sci; 2021; 17(6):1446-1460. PubMed ID: 33907508
[TBL] [Abstract][Full Text] [Related]
12. Latest in COVID-19 Vaccine 'Candidates' Race.
Atoum MF; Zreig DA; Abu Zreig LM
Infect Disord Drug Targets; 2023; 23(1):e180822207640. PubMed ID: 35984031
[TBL] [Abstract][Full Text] [Related]
13. A COVID-19 vaccine-dare to dream.
Phillis A
Br J Community Nurs; 2020 Dec; 25(12):2-7. PubMed ID: 33275510
[TBL] [Abstract][Full Text] [Related]
14. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
Gudadappanavar AM; Benni J
J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964
[TBL] [Abstract][Full Text] [Related]
15. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
Jafari A; Danesh Pouya F; Niknam Z; Abdollahpour-Alitappeh M; Rezaei-Tavirani M; Rasmi Y
Mol Biol Rep; 2022 Jun; 49(6):4943-4957. PubMed ID: 35235159
[TBL] [Abstract][Full Text] [Related]
16. Efforts towards a COVID-19 vaccine.
Brüssow H
Environ Microbiol; 2020 Oct; 22(10):4071-4084. PubMed ID: 32893468
[TBL] [Abstract][Full Text] [Related]
17. The race for a COVID-19 vaccine: where are we up to?
Hossain MK; Hassanzadeganroudsari M; Feehan J; Apostolopoulos V
Expert Rev Vaccines; 2022 Mar; 21(3):355-376. PubMed ID: 34937492
[TBL] [Abstract][Full Text] [Related]
18. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.
Zellweger RM; Wartel TA; Marks F; Song M; Kim JH
Expert Rev Vaccines; 2020 Aug; 19(8):691-698. PubMed ID: 32838605
[TBL] [Abstract][Full Text] [Related]
19. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
Behr MA; Divangahi M; Schurr E
J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
[TBL] [Abstract][Full Text] [Related]
20. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.
Jin P; Li J; Pan H; Wu Y; Zhu F
Signal Transduct Target Ther; 2021 Feb; 6(1):48. PubMed ID: 33531462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
